AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3.
Wunderlich
M
M
Chou
F-S
FS
Link
K A
KA
Mizukawa
B
B
Perry
R L
RL
Carroll
M
M
Mulloy
J C
JC
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D005434:Flow Cytometry; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism*; D006801:Humans; D053631:Interleukin Receptor Common gamma Subunit / Q000502:physiology*; D007377:Interleukin-3 / Q000378:metabolism*; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D008297:Male; D051379:Mice; D016688:Mice, Inbred NOD; D018345:Mice, Knockout; D016513:Mice, SCID; D012333:RNA, Messenger / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019089:Stem Cell Factor / Q000378:metabolism*; D023041:Xenograft Model Antitumor Assays
C507942:Il2rg protein, mouse; D053631:Interleukin Receptor Common gamma Subunit; D007377:Interleukin-3; D012333:RNA, Messenger; D019089:Stem Cell Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor